Research Grants in Clinical Informatics (R01 Clinical Trial Optional)
Grant Opportunity Analysis
The National Institutes of Health (NIH), through the National Library of Medicine (NLM), is offering Research Grants in Clinical Informatics (R01 Clinical Trial Optional) under Funding Opportunity Number PAR-26-042. This grant aims to support innovative research that develops methodologies to empower clinicians, patients, and the public in understanding, managing, and improving health and healthcare delivery, with a focus on scalable and reusable approaches for managing health-related digital objects. The program is crucial for transforming heterogeneous health data into actionable knowledge, ultimately enhancing clinical workflows and health outcomes. Eligible applicants include various organizations, with specific restrictions on foreign subawards, and funding is capped at $250,000 per year for a maximum of four years. Applications are due by February 5, 2029, and interested parties can contact NLM at NLMProgram@nih.gov for further information.
Eligible Applicants
Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/International CollaborationsNon-domestic (non-U.S.) Entities (Foreign Organizations) are eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are allowed.NIH will no longer issue awards (i.e., new, renewal, or non-competing continuation) to domestic or foreign entities that involve foreign subawards/subcontracts. All NIH-funded research involving foreign subawards/subcontracts must be submitted in response to a NOFO that is specifically designated for funded international collaborations. This new requirement was effective, May 1, 2025.Applications involving foreign subawards/subcontracts submitted in response to this NOFO will be deemed noncompliant and will not be considered for funding. This policy applies to all monetary international collaborations resulting in foreign subawards/subcontracts, however, it does not preclude unfunded international collaborations or foreign components, funding for foreign consultants, or procurement of unique equipment or supplies from foreign vendors.